Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder

Pharmacopsychiatry

Volumn 43, Issue 2, 2010, Pages 45-49

  Walderhaug, E ^a,b   Kasserman, S ^b   Aikins, D ^a,b   Vojvoda, D ^b   Nishimura, C ^b   Neumeister, A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPOSALIVATION; INCREASED DREAM ACTIVITY; INNER UNREST; LIBIDO DISORDER; MALE; MENTAL STRESS; MICTURITION DISORDER; NATURALISTIC INQUIRY; NAUSEA; NIGHTMARE; OPEN STUDY; ORGASM DISORDER; PHOTOSENSITIVITY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; SYMPTOM; WEIGHT REDUCTION;

COMBAT DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DREAMS; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VETERANS; WAR;

EID: 77949905575     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1237694     Document Type: Article

References (61)

1. American Psychiatric Association AP. Diagnostic and Statistical Manual of Mental Disorders Washington, DC: American Psychiatric Association 1994
2. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001 62 (Suppl 12) 5-9
3. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006 188 273-280
4. Blake DD, Weathers FW, Nagy LM et al. The development of a clinician-administered PTSD scale. J Trauma Stress 1995 8 75-90
5. Blanchard EB, Jones-Alexander J, Buckley TC et al. Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther 1996 34 669-673
6. Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 2001 62 (Suppl 4) 7-11; discussion 37-40
7. Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001 26 37-43
8. Boscarino JA. Posttraumatic stress disorder and mortality among U. S. Army veterans 30 years after military service. Ann Epidemiol 2006 16 248-256
9. Campbell DG, Felker BL, Liu CF et al. Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med 2007 22 711-718
10. Davidson JR. Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson trauma scale, clinical global impressions and the clinician-administered PTSD scale. Int Clin Psychopharmacol 2004 19 85-87
11. Davis LL, Ward C, Rasmusson A et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008 41 8-18
12. De Berardis D, Serroni N, Carano A et al. The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2008 4 929-935
13. Delgado PL, Brannan SK, Mallinckrodt CH et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005 66 686-692
14. Deneys ML, Ahearn EP. Exacerbation of PTSD symptoms with use of duloxetine. J Clin Psychiatry 2006 67 496-497
15. Dickerson F, Kirkpatrick B, Boronow J et al. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 2006 32 396-400
16. Dieperink M, Erbes C, Leskela J et al. Comparison of treatment for post-traumatic stress disorder among three Department of Veterans Affairs medical centers. Mil Med 2005 170 305-308
17. Dierks MR, Jordan JK, Sheehan AH. Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother 2007 41 1013-1017
18. Dohrenwend BP, Turner JB, Turse NA et al. The psychological risks of Vietnam for US veterans: a revisit with new data and methods. Science 2006 313 979-982
19. Frankle WG, Slifstein M, Gunn RN et al. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. J Nucl Med 2006 47 815-826
20. Goldstein BI, Diamantouros A, Schaffer A et al. Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs 2006 66 1229-1237
21. Green BL, Krupnick JL, Chung J et al. Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychol 2006 62 815-835
22. Guy W. ECDEU assessmnet manual for psychopharmacology In: National Institute of Mental Health PRB, ed. Rockville: National Institutes of Health 1976 217-222
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959 50-55
24. Hanretta AT, Malek-Ahmadi P. Combined use of ECT with duloxetine and olanzapine: a case report. J ECT 2006 22 139-141
25. Hoge CW, Terhakopian A, Castro CA et al. Association of posttraumatic stress disorder with somatic symptoms, health care visits, and absenteeism among Iraq war veterans. Am J Psychiatry 2007 164 150-153
26. Hudson JI, Wohlreich MM, Kajdasz DK et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005 20 327-341
27. Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disordera systematic review and meta-analysis. S Afr Med J 2006 96 1088-1096
28. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002 8 361-376
29. Keane TM, Marshall AD, Taft CT. Posttraumatic stress disorder: etiology, epidemiology, and treatment outcome. Annu Rev Clin Psychol 2006 2 161-197
30. Kolkow TT, Spira JL, Morse JS et al. Post-traumatic stress disorder and depression in health care providers returning from deployment to Iraq and Afghanistan. Mil Med 2007 172 451-455
31. Krakow B, Germain A, Warner TD et al. The relationship of sleep quality and posttraumatic stress to potential sleep disorders in sexual assault survivors with nightmares, insomnia, and PTSD. J Trauma Stress 2001 14 647-665
32. Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res 2009 March 28 [Epub ahead of print]
33. rd et al. Prospective study of posttraumatic stress disorder symptoms and coronary heart disease in the normative aging study. Arch Gen Psychiatry 2007 64 109-116
34. Lerer E, Kanyas K, Karni O et al. Why do young women smoke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Mol Psychiatry 2006 11 771-781
35. Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987 334 1-100
36. Mallinckrodt CH, Prakash A, Andorn AC et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006 40 337-348
37. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001 7 541-547
38. McGhee LL, Maani CV, Garza TH et al. The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 2009 30 92-97
39. Miller LJ. Prazosin for the treatment of posttraumatic stress disorder sleep disturbances. Pharmacotherapy 2008 28 656-666
40. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 134 382-389
41. Nemeroff CB, Bremner JD, Foa EB et al. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res 2006 40 1-21
42. Neylan TC, Lenoci M, Samuelson KW et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006 163 2186-2188
43. Oquendo M, Brent DA, Birmaher B et al. Posttraumatic stress disorder comorbid with major depression: factors mediating the association with suicidal behavior. Am J Psychiatry 2005 162 560-566
44. Orr SP, Metzger LJ, Lasko NB et al. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000 109 290-298
45. Pfefferbaum A, Adalsteinsson E, Bell RL et al. Development and resolution of brain lesions caused by pyrithiamine- and dietary-induced thiamine deficiency and alcohol exposure in the alcohol-preferring rat: a longitudinal magnetic resonance imaging and spectroscopy study. Neuropsychopharmacology 2007 32 1159-1177
46. Pfefferbaum A, Adalsteinsson E, Sullivan EV. Dysmorphology and microstructural degradation of the corpus callosum: Interaction of age and alcoholism. Neurobiol Aging 2006 27 994-1009
47. Pjrek E, Willeit M, Praschak-Rieder N et al. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry 2008 41 100-105
48. Ravindran LN, Stein MB. Pharmacotherapy of PTSD: Premises, principles, and priorities. Brain Res 2009 March 28 [Epub ahead of print]
49. Rothbaum BO, Davidson JR, Stein DJ et al. A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. J Clin Psychiatry 2008 69 1529-1539
50. Rynn M, Russell J, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008 25 182-189
51. Sareen J, Cox BJ, Afifi TO et al. Combat and peacekeeping operations in relation to prevalence of mental disorders and perceived need for mental health care: findings from a large representative sample of military personnel. Arch Gen Psychiatry 2007 64 843-852
52. Schnurr PP, Hayes AF, Lunney CA et al. Longitudinal analysis of the relationship between symptoms and quality of life in veterans treated for posttraumatic stress disorder. J Consult Clin Psychol 2006 74 707-713
53. Seal KH, Bertenthal D, Miner CR et al. Bringing the war back home: mental health disorders among 103788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Intern Med 2007 167 476-482
54. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006 CD002795
55. Stein DJ, Pedersen R, Rothbaum BO et al. Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: A pooled analysis. Int J Neuropsychopharmacol 2009 12 23-31
56. Stein MB, Kerridge C, Dimsdale JE et al. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007 20 923-932
57. Sullivan EV, Adalsteinsson E, Sood R et al. Longitudinal brain magnetic resonance imaging study of the alcohol-preferring rat. Part I: adult brain growth. Alcohol Clin Exp Res 2006 30 1234-1247
58. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001 178 234-241
59. Vieweg WV, Julius DA, Fernandez A et al. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006 119 383-390
60. Zatzick DF, Marmar CR, Weiss DS et al. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1997 154 1690-1695
61. Ziegenhorn AA, Roepke S, Schommer NC et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2009 29 170-173